ArticleNature communications2019
Rapid selection and identification of functional CD8
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 48 citations in OpenAlex.
- Preimmunization of SPF Mice With Capsid Virus-like Particle Has no Effect on CD8Clinical and translational science · 2026Article
- Comprehensive self-antigen screening to assess cross-reactivity in promiscuous T-cell receptors.Frontiers in immunology · 2025Article
- Article
- A synthetic cytotoxic T cell platform for rapidly prototyping TCR function.NPJ precision oncology · 2024Article
- Integrative nomogram model based on anoikis-related genes enhances prognostic evaluation in colorectal cancer.Heliyon · 2024Article
- Tsyn-Seq: a T-cell Synapse-Based Antigen Identification Platform.Cancer immunology research · 2024Article
- De novo identification of CD4Nature methods · 2024Article
- Deciphering Membrane-Protein Interactions and High-Throughput Antigen Identification with Cell Doublets.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- T-FINDER: A highly sensitive, pan-HLA platform for functional T cell receptor and ligand discovery.Science advances · 2024Article
- Review
- Article
- Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges.Biomarker research · 2023Review
- A Synthetic Cytotoxic T cell Platform for Rapidly Prototyping TCR Function.bioRxiv : the preprint server for biology · 2023Article
- Dynamics and specificities of T cells in cancer immunotherapy.Nature reviews. Cancer · 2023Review
- Review
- Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.Frontiers in immunology · 2023Review
- Optical sensing and control of T cell signaling pathways.Frontiers in physiology · 2023Review
- Engineered retroviruses map ligand-receptor interactions.Nature methods · 2022Article
- Antigen identification and high-throughput interaction mapping by reprogramming viral entry.Nature methods · 2022Article
- Functional Profile of CD8Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.